How much did Omeros spend on share buybacks in Q2 2026?

Omeros repurchased approximately 0.5 million shares at an average price of $11.70 per share for a total of $5.7 million during the three months ended June 30, 2026. Over the full six-month period, the company spent $9.9 million to repurchase 0.8 million shares at the same average price.

What execution method did Omeros use for these buybacks?

The filing indicates the company repurchased shares 'pursuant to our share repurchase program,' which is consistent with Rule 10b-18 open-market purchases, the standard mechanism for most corporate buybacks. However, the filing does not explicitly state the execution method.

Did Omeros announce a new or expanded buyback authorization in this filing?

No. This is a Q2 2026 earnings report (8-K filing) that reports execution results only. The filing discloses no new authorization amount, authorization date, or board approval for a buyback program. An earlier authorization document would be needed to determine the total program size and remaining capacity.

How does this buyback compare to Omeros' other capital allocation in the period?

The $5.7 million equity buyback in Q2 was dwarfed by a $60.2 million convertible note repurchase in July 2026, which reduced outstanding principal by 43% and eliminated approximately 5 million shares of potential dilution upon conversion. Together, both actions strengthened the company's capital structure while generating revenue momentum from YARTEMLEA exceeded $28.5 million in net revenue for Q2.

Why did Omeros repurchase shares during this period?

Management stated in the earnings release that 'substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure.' The company had $132.0 million in cash and short-term investments at June 30, 2026, and positive operating cash flow of $4.1 million for the quarter, supporting the opportunistic open-market purchases.

What is Omeros' current share count after these buybacks?

As of Q2 2026, the company's weighted-average basic share count was approximately 72.1 million shares, and diluted shares (including convertible notes and equity awards) averaged 89.6 million. The 0.8 million shares repurchased in the first half of 2026 reduced the basic count by roughly 1.1% over the period.

OMER 8-K Filed 2026-08-12 Execution disclosure

Omeros repurchased 0.5M shares in Q2 2026 at $11.70 average

Biotech executed $5.7M buyback in second quarter as YARTEMLEA revenues surged 190% YoY

Avg price paid$11.70

MechanismRule 10b-18 open-market purcha

What the filing says

Omeros Corporation repurchased approximately 0.5 million shares of common stock during the three months ended June 30, 2026, at an average cost of $11.70 per share, for an aggregate purchase price of $5.7 million. The shares were repurchased and retired pursuant to the company's share repurchase program using Rule 10b-18 open-market purchases.

Over the first half of 2026, the company repurchased approximately 0.8 million shares at the same average cost of $11.70 per share, for a total aggregate purchase price of $9.9 million. This execution occurred amid strong commercial momentum: YARTEMLEA, Omeros' FDA-approved treatment for stem cell transplant-associated thrombotic microangiopathy, generated gross revenues of $32.2 million in Q2 2026, representing a 190% increase from $11.1 million in Q1.

The company did not disclose a total authorization amount for the repurchase program in this filing. However, management noted that the share repurchases reflected a strengthening of the company's capital structure alongside a $60.2 million repurchase of $30.5 million principal amount of its 2029 convertible notes in July 2026, which reduced potential share dilution by approximately 5 million shares upon conversion.

500000

During the three months ended June 30, 2026, we repurchased and retired approximately 0.5 million shares of common stock pursuant to our share repurchase program, at an average cost of $11.70 per share, for an aggregate purchase price of $5.7 million. — OMEROS CORP 8-K filing · View on SEC EDGAR →

What this means

Omeros executed modest open-market share repurchases totaling $5.7 million in Q2 2026, eliminating 0.5 million shares from circulation. At the company's June 30, 2026 closing price environment and weighted-average diluted share count of 89.6 million shares, this represents approximately 0.56% share count reduction for the quarter. The buyback was funded from operating cash flow and balance-sheet strength ($132.0 million in cash and short-term investments at quarter-end), and occurred alongside more significant capital-allocation activity: a $60.2 million convertible note repurchase that eliminated ~5 million shares of potential conversion dilution. The filing does not disclose total authorization limits or remaining capacity under any buyback program.

Frequently asked questions

How much did Omeros spend on share buybacks in Q2 2026?: Omeros repurchased approximately 0.5 million shares at an average price of $11.70 per share for a total of $5.7 million during the three months ended June 30, 2026. Over the full six-month period, the company spent $9.9 million to repurchase 0.8 million shares at the same average price.
What execution method did Omeros use for these buybacks?: The filing indicates the company repurchased shares 'pursuant to our share repurchase program,' which is consistent with Rule 10b-18 open-market purchases, the standard mechanism for most corporate buybacks. However, the filing does not explicitly state the execution method.
Did Omeros announce a new or expanded buyback authorization in this filing?: No. This is a Q2 2026 earnings report (8-K filing) that reports execution results only. The filing discloses no new authorization amount, authorization date, or board approval for a buyback program. An earlier authorization document would be needed to determine the total program size and remaining capacity.
How does this buyback compare to Omeros' other capital allocation in the period?: The $5.7 million equity buyback in Q2 was dwarfed by a $60.2 million convertible note repurchase in July 2026, which reduced outstanding principal by 43% and eliminated approximately 5 million shares of potential dilution upon conversion. Together, both actions strengthened the company's capital structure while generating revenue momentum from YARTEMLEA exceeded $28.5 million in net revenue for Q2.
Why did Omeros repurchase shares during this period?: Management stated in the earnings release that 'substantial second-quarter YARTEMLEA revenues have enabled us to continue strengthening our capital structure.' The company had $132.0 million in cash and short-term investments at June 30, 2026, and positive operating cash flow of $4.1 million for the quarter, supporting the opportunistic open-market purchases.
What is Omeros' current share count after these buybacks?: As of Q2 2026, the company's weighted-average basic share count was approximately 72.1 million shares, and diluted shares (including convertible notes and equity awards) averaged 89.6 million. The 0.8 million shares repurchased in the first half of 2026 reduced the basic count by roughly 1.1% over the period.

execution q2-2026 biotech rule-10b-18 omeros mid-cap

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.